Business
Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for this year.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
Although the COVID-19 death toll has not yet reached the numbers of H3N2, it still continues to climb.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
In its daily blog about the precautions the company is taking to ensure continued service to the world, Amazon said it will build its own testing facilities for employees.
On Thursday, the American Medical Association doubled down on its stance against using off-label medicines like hydroxychloroquine and chloroquine to treat COVID-19 patients.
As COVID-19 has swept across the world, companies have had to make significant adjustments to the way business is conducted in a global economy. It has impacted all types of operations, including clinical trials.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
Biopharma companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
If you’re having trouble keeping up with multiple industry programs aimed at COVID-19, you’re not alone. But, there is a new solution that can help you see the proverbial forest from the trees – Signals Analytics COVID-19 Playbook.
Biopharma companies are attacking the COVID-19 pandemic from many fronts. Emergent BioSolutions is among those leading the fight.